Orion Biotechnology Canada Ltd. has officially announced a US $5 million private financing which was closed late 2017 with undisclosed Canadian and international investors.
[mepr-active rule=”374″ ifallowed=”hide”]#SUBSCRIBERS ONLY CONTENT Where and how did you get your news? Subscribe today to see our research on this and all other subscriber ONLY news. See what you have been missing and be informed!#[/mepr-active][mepr-active rule=”374″]Orion Biotechnology Canada board of directors is comprised of Chairman Rudolf Bom (Malta), CEO Mark Groper (Ottawa), COO Anatolii Klepatskyi (Ottawa), and Dmitry Martynenko (Ukraine). Martynenko is reportedly a director of Kyiv International Airport since 2011. He is also Legal Counsel to President of the privately owned UDP (Ukrainian Development Partners) Group which is a major shareholder of Kyiv International Airport.[/mepr-active]
Orion Biotechnology Canada is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases.
With operations in Shanghai, China, Kraków, Poland, and Genève, Switzerland, Orion brings together innovative technologies from some of the world’s leading research institutions such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University.
“We are delighted to have secured the financial resources during this period of rapid expansion,” said Mark Groper, President and Chief Executive Officer. “This financing allows Orion, as a private company, to continue development of its expanding pipeline of innovative products, including expansion of our infrastructure and human resources. It also provides external validation of the unique value proposition of the company’s pipeline products which include candidates in the areas of Sexual Health, Oncology and Multiple Sclerosis.
“This is a unique product which has significant potential,” said Dr. Ian McGowan, Chief Scientific Officer of Orion. “Antiretroviral microbicide candidates have activity against HIV, and in some cases HSV-2, but lack contraceptive efficacy. In contrast, Orion’s unique non-antiretroviral product could have the potential to protect against both HIV infection and pregnancy without the need for voluntary counselling and testing for HIV infection. There is no doubt that such a product would be a valuable addition to the sexual health armamentarium.”
Rudolf Bom, founder and Chairman of Orion Biotechnology Canada Ltd., said “Orion Biotechnology is an example of the kind of exciting and innovative results that can be realized when world-class science comes together with entrepreneurial and seasoned capital investors. Orion is now in a position to rapidly advance several of its innovative solutions toward the clinic.”
Orion Biotechnology Canada